Autonomix Reports Strong Pain Relief And Opioid Reduction In First Human Trial For Pancreatic Cancer Pain

Autonomix Medical, Inc., a medical device company innovating nerve-targeting therapies, has released a compelling patient testimonial video from its first-in-human proof-of-concept trial (PoC 1). This trial evaluated the safety and effectiveness of Autonomix’s transvascular nerve ablation technology in treating severe pancreatic cancer pain. After meeting its clinical objectives, the company enrolled 20 patients and concluded the initial study phase.

Brad Hauser, Chief Executive Officer of Autonomix, stated, “We are deeply grateful to the patients who have shared their experiences with us. Testimonials like this provide meaningful insight into our technology's real-world impact, particularly in improving quality of life and reducing dependence on pain medication. Patients with late-stage pancreatic cancer face severe, often unrelenting pain. Data from our ongoing study reinforce the significant burden this pain places on quality of life and point to a clear, unmet need for innovative interventional pain management solutions.”

Trial results showed that patients experienced significant pain relief as early as 24 hours post-procedure. On average, participants reported a 53.3% reduction in pain at 7 days and a 59.2% reduction at 4–6 weeks, as measured by the Visual Analogue Scale (VAS). Additionally, 100% of responders were opioid-free by Day 7, with 73% remaining off opioids by 4–6 weeks. The procedure also demonstrated a strong safety profile, with no device- or procedure-related serious adverse events.

The positive results have encouraged Autonomix to initiate a second phase (PoC 2) that will treat pain from various visceral cancers and address moderate to severe pain in early-stage pancreatic cancer patients.